Press Releases on September 17, 2018 - EIN Presswire - Press Release Distribution Service

Published on September 17, 2018 - 12:25 GMT

Human medicines European public assessment report (EPAR): Briviact (in Italy: Nubriveo), brivaracetam, Epilepsy, Date of ...

Briviact can only be obtained with a prescription. The medicine is available as tablets, an oral solution (a liquid taken by mouth) and a solution for injection or infusion (drip) into a vein, which is used when the medicine cannot be given by mouth. The …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:25 GMT

Human medicines European public assessment report (EPAR): Briviact (in Italy: Nubriveo), brivaracetam, Epilepsy, Date of ...

Briviact can only be obtained with a prescription. The medicine is available as tablets, an oral solution (a liquid taken by mouth) and a solution for injection or infusion (drip) into a vein, which is used when the medicine cannot be given by mouth. The …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:25 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Momelotinib, decision type: , therapeutic area: , PIP number: P/0157/...

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:25 GMT

Human medicines European public assessment report (EPAR): Aprovel, irbesartan, Hypertension, Date of authorisation: 26/08/1997, ...

Aprovel was originally studied in 11 trials for its effects on blood pressure. Aprovel was compared with placebo (a dummy treatment) in 712 patients and with other medicines for hypertension (atenolol, enalapril or amlodipine) in 823 patients. Its use in …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:25 GMT

Human medicines European public assessment report (EPAR): Aprovel, irbesartan, Hypertension, Date of authorisation: 26/08/1997, ...

Aprovel was originally studied in 11 trials for its effects on blood pressure. Aprovel was compared with placebo (a dummy treatment) in 712 patients and with other medicines for hypertension (atenolol, enalapril or amlodipine) in 823 patients. Its use in …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:25 GMT

Human medicines European public assessment report (EPAR): Adenuric, febuxostat, Gout, Date of authorisation: 21/04/2008, Revision: ...

For the treatment of hyperuricaemia and gout, Adenuric has been studied in two main studies involving a total of 1,834 patients. The first study, carried out in 1,072 patients, compared three doses of Adenuric (80, 120 and 240 mg once a day) with placebo …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:25 GMT

Human medicines European public assessment report (EPAR): Trisenox, arsenic trioxide, Leukemia, Promyelocytic, Acute, Date of ...

Trisenox is indicated for induction of remission, and consolidation in adult patients with: Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤ 10 x 103/µl) in combination with all‑trans‑retinoic acid ( …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:25 GMT

Human medicines European public assessment report (EPAR): Trisenox, arsenic trioxide, Leukemia, Promyelocytic, Acute, Date of ...

Trisenox is indicated for induction of remission, and consolidation in adult patients with: Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤ 10 x 103/µl) in combination with all‑trans‑retinoic acid ( …

Distribution channels: Healthcare & Pharmaceuticals Industry